OPTIMAL Data Support TLX597-Tx as a Next-Gen Radioligand Therapy in Prostate Cancer

AidaBREAST Gains FDA Breakthrough Status for Personalized Radiotherapy in Breast Cancer

Phase 3 MagnetisMM-5 Trial Supports Earlier Use of Elranatamab in Relapsed Myeloma

Dual Pathway Blockade Achieves 40% Response in Clear Cell Gynaecological Cancer

World’s First Nectin-4-Targeting ADC Enters Phase III Trial in Triple-Negative Breast Cancer

Long-Term Data Show Taletrectinib Delivers High Response Rates in ROS1+ NSCLC

FDA-Cleared Utepreva Device Aims to Improve Early Endometrial Cancer Detection

PLN-101095 Plus Pembrolizumab Shows Durable Responses in ICI-R Solid Tumors

Opaganib Shows Dual Preclinical Promise in Neuroblastoma and Triple- Breast Cancer

Ozekibart Shows Encouraging Late-Line Activity in Metastatic Colorectal Cancer

FDA Grants Breakthrough Status to First Viral Liquid Biopsy in Hepatocellular Carcinoma

FDA Gives Priority Review to PADCEV Plus Pembrolizumab in MI Bladder Cancer

AACR26 Data Show Multi-Biomarker MCED Approach Improves Early Cancer Detection

FDA Grants Breakthrough Status to First Urine-Based Multi-Cancer Early Detection Test

Daraxonrasib Doubles Overall Survival in Previously Treated Metastatic Pancreatic Cancer

AI Nodule Detection Helps Sarasota Memorial Reach 75% Early Lung Cancer Diagnosis

Illumina Launch 100 K Genome Effort to Advance Cancer and Rare Disease Research

Zenocutuzumab Gains NCCN Support as FDA Review Advances in Cholangiocarcinoma

Phase 2 Data Position Trastuzumab Pamirtecan as a Promising Option in Endometrial Cancer

Mocertatug Rezetecan Shows Strong Responses in Ovarian and Endometrial Cancers

FDA Grants Priority Review to Ifinatamab Deruxtecan in Pretreated ES-SC Lung Cancer

MD Anderson Study Identifies DPY30 as Therapeutic Target in Pancreatic Cancer

Blocking DHODH Helps Triple Combination Overcome Resistance in Lung Cancer

Neladalkib Reaches FDA Review for TKI-Pretreated ALK+ Non-Small Cell Lung Cancer

FDA Grants Breakthrough Status to WU-CART-007 for T-Cell Leukemias and Lymphomas

AI Predicts Chemotherapy Benefit in Breast Cancer Using Routine Pathology Slides

FDA Approves Agilent’s PD-L1 Test to Guide KEYTRUDA Use in Esophageal and GEJ Carcinoma

New Protein Modification Linked to IDH-Mutant Cancers Opens Therapeutic Possibilities

BioNTech Showcases Promising Bispecific and ADC Data in Lung Cancer at ELCC 2026

Sunvozertinib Outperforms Chemo in First-Line EGFR Exon 20 Insertion NSC Lung Cancer

TG Therapeutics Secures $500M to Advance BRIUMVI in Relapsing Multiple Sclerosis

Targeted Bladder Cancer Therapy Erda-iDRS Achieves 89% Response Rate and PDC

Atirmociclib Reduces Progression Risk by 40% in CDK4/6 Metastatic Breast Cancer

TALAPRO-3 Trial Supports Early Use of Talazoparib in HRR+ mCS Prostate Cancer

FDA Approves Nivolumab-AVD as First Immunotherapy Combination for Hodgkin Lymphoma

Abenacianine Enters Phase 3 to Enhance Real-Time Tumor Detection in Lung Surgery

CellCarta Secures Global Exclusivity for Aspyre Lung to Advance Lung Cancer Testing

Romiplostim Prevents Chemotherapy Side Effects and Preserves Treatment Intensity

PSMA PET/CT May Transform Prostate Cancer Diagnosis and Reduce Biopsies by 50%

Designing Digital Healthcare Systems for the Future of Patient-Centered Care

Amivantamab Plus Chemotherapy Shows Promising Responses in Colorectal Cancer

Novartis Expands US Radioligand Manufacturing With $23 Billion Investment in Florida

Rewiring RNA: Antisense RNA Therapy Exposes a New Weakness in Pancreatic Cancer

FDA Approves First Subcutaneous Amivantamab Plus Lazertinib for EGFR+ Lung Cancer

Platinum-Free PADCEV Plus Pembrolizumab Improves Survival in MI Bladder Cancer

FDA Approves T-DXd Plus Pertuzumab as a First-Line Standard in HER2+ Breast Cancer

Teclistamab plus Daratumumab Achieves an 83% Risk Reduction in R/R Multiple Myeloma

FDA Approves AKEEGA for BRCA2+ Prostate Cancer as the First Precision Therapy

GSK’s ADC Risvutatug Rezetecan Earns FDA Orphan Drug Status for Small Cell Lung Cancer

Ribociclib Maintains Long-Term Disease Control in HR+ HER2 Metastatic Breast Cancer